Respiratory failure & ventilation

Machine learning models compared with current clinical indices to predict the outcome of high flow nasal cannula therapy in acute hypoxemic respiratory failure

Crit CarePublished Prognostic model development and external validation study

Authors' conclusion

Decision support tools based on SVM models could provide clinicians with more accurate early predictions of HFNC outcome than currently available clinical indices.

Study context

Population
Patients with acute hypoxemic respiratory failure treated with high-flow nasal cannula (HFNC); development at the respiratory ICU of the University Hospital of Modena (2018–2023), external validation in RENOVATE trial (Brazil) and MIMIC-IV/eICU (US)development
Participants
184 patients
Comparison
Support Vector Machine (SVM) machine learning (ML) model vs clinical indices for predicting HFNC outcome
Outcome
Prediction of HFNC outcome (failure) from measurements made within the first 2 h of treatment
Follow-up
First 2 h of treatment
Methodological detailsmachine learning, internal and external validation
  • Machine learning
  • Internal and external validation

Performance

As reported in the abstract

Prediction of HFNC failure, external validation (567-patient dataset)
Test or modelAUCSensitivitySpecificityAccuracy
SVM0.7973%73%73%
ROX index0.7479%60%64%

AUC

SVM0.79
ROX index0.74

Sensitivity

SVM73%
ROX index79%

Specificity

SVM73%
ROX index60%

Accuracy

SVM73%
ROX index64%

Further findings

OutcomeSVM with ABGModified ROX index
Prediction of HFNC failure with ABG measurements, external validation (MIMIC-IV/eICU dataset)
Accuracy83%70%
Sensitivity84%63%
Specificity82%74%
AUC0.820.65

Original publication

Machine learning models compared with current clinical indices to predict the outcome of high flow nasal cannula therapy in acute hypoxemic respiratory failure. Crit Care. Published 7 March 2025. doi:10.1186/s13054-025-05336-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.